431 related articles for article (PubMed ID: 11504769)
21. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
22. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein substrates and antagonists cluster into two distinct groups.
Scala S; Akhmed N; Rao US; Paull K; Lan LB; Dickstein B; Lee JS; Elgemeie GH; Stein WD; Bates SE
Mol Pharmacol; 1997 Jun; 51(6):1024-33. PubMed ID: 9187269
[TBL] [Abstract][Full Text] [Related]
24. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
[TBL] [Abstract][Full Text] [Related]
25. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
Leonessa F; Green D; Licht T; Wright A; Wingate-Legette K; Lippman J; Gottesman MM; Clarke R
Br J Cancer; 1996 Jan; 73(2):154-61. PubMed ID: 8546900
[TBL] [Abstract][Full Text] [Related]
26. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
28. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
29. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
30. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
[TBL] [Abstract][Full Text] [Related]
31. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
32. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
33. Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein.
Li D; Au JL
Pharm Res; 2001 Jul; 18(7):907-13. PubMed ID: 11496948
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
[TBL] [Abstract][Full Text] [Related]
35. Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer.
Shanmugam T; Joshi N; Ahamad N; Deshmukh A; Banerjee R
Int J Pharm; 2020 Aug; 586():119482. PubMed ID: 32492505
[TBL] [Abstract][Full Text] [Related]
36. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Ehrlichova M; Vaclavikova R; Ojima I; Pepe A; Kuznetsova LV; Chen J; Truksa J; Kovar J; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):95-105. PubMed ID: 16059735
[TBL] [Abstract][Full Text] [Related]
37. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.
Yen WC; Wientjes MG; Au JL
Pharm Res; 1996 Sep; 13(9):1305-12. PubMed ID: 8893266
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein efflux pump expression and activity in Calu-3 cells.
Hamilton KO; Backstrom G; Yazdanian MA; Audus KL
J Pharm Sci; 2001 May; 90(5):647-58. PubMed ID: 11288109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
